Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Phase 2
50
about 9 years
18+
1 site in TX
What this study is about
This trial is testing a treatment with enasidenib and azacitidine for patients whose acute myeloid leukemia has returned (recurrent) or not responded to previous treatments (refractory). This treatment may help stop cancer cells from growing by blocking certain enzymes involved in cell growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine
- 2.Take Enasidenib Mesylate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, Antineoplastic Agent [TC]
injection, subcutaneous, oral (Oral Tablet)
Primary: Overall response rate (ORR)
Secondary: Disease-free survival (DFS), Duration of response, Event-free survival, Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, Overall survival (OS)
Oncology